Bio-Techne rebrands genome engineering as part of R&D Systems portfolio

By The Science Advisory Board staff writers

September 21, 2020 -- Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.

The company's B-MoGen Biotechnologies portfolio of genome engineering services, good manufacturing practice therapeutic manufacturing services, and proprietary transposon-transposase gene transfer system, TcBuster, has been rebranded under R&D Systems.

As part of the rebranding, the B-MoGen Biotechnologies website will be retired. All service details and purchasing options will be maintained on the R&D Systems website. The consolidation will help the company provide customers with discovery-to-clinic cell and gene therapy solutions.

Bio-Techne, Leica launch RNA probes for COVID-19 research
Bio-Techne and Leica Biosystems have announced the automation of RNAscope COVID-19 probes on Bond Rx, Leica's staining platform, for research use only....
Bio-Techne releases new SARS recombinant antibody
Bio-Techne has launched a SARS-CoV-1/2 spike receptor-binding domain LlamaBody recombinant antibody that blocks the virus from binding to the host receptor,...
Bio-Techne, Kantaro launch COVID-19 serology test
Bio-Techne and Kantaro Biosciences have launched COVID-SeroIndex, a quantitative SARS-CoV-2 immunoglobulin G antibody research-use only kit.
Bio-Techne releases product for manufacturing
Bio-Techne has released GMP ProDots Proteins to support cell and gene therapy manufacturing workflows. The product will allow manufacturers to safely...
Bio-Techne releases new T-cell activation kit
Bio-Techne has released a new kit for cell and gene therapy manufacturing called GMP Cloudz Human T Cell Activation.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter